Validity of Self-Reports of Return for Routine Repeat Screening in an Ovarian Cancer Screening Program

  1. Emily L.B. Lykins1,
  2. Edward L. Pavlik2 and
  3. Michael A. Andrykowski1
  1. Departments of 1Behavioral Science and 2Obstetrics and Gynecology, University of Kentucky, Lexington, Kentucky
  1. Requests for reprints:
    Michael A. Andrykowski, Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY 40536-0086. E-mail: mandry{at}uky.edu

Abstract

Cancer screening research relies on reliable and valid measurement of cancer screening behavior. Self-reports of screening constitute a cost-effective approach to measuring screening behavior; however, demonstration of suitable validity of these self-reports is critical. We evaluated the validity of self-report of return for repeat, routine, annual transvaginal sonography (TVS) screening for ovarian cancer. Participants (n = 535) in a university-based ovarian cancer screening program for asymptomatic, average risk women completed a telephone interview 18 months following an initial, baseline TVS screening test. Self-reports of return for a repeat, routine ovarian cancer screening test since baseline were obtained and compared with objective records of repeat screening from the screening program database. Overall agreement of self-reports and objective records of ovarian cancer screening was 97.57% (κ = 0.94). Sensitivity was 0.98, specificity was 0.96, positive predictive value was 0.98, and negative predictive value was 0.96. The month of last screening was accurately identified by 80% of participants. It was concluded the validity of self-reports of TVS screening for ovarian cancer is very high and may even exceed the validity of self-reports of participation in breast, cervical, and colorectal cancer screening over similar recall periods. Consequently, self-reports of TVS screening may serve as a cost-effective substitute for more objective methods of assessing TVS screening behavior. (Cancer Epidemiol Biomarkers Prev 2007;16(3):490–3)

Footnotes

  • Grant support: National Cancer Institute grant CA84036.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted January 2, 2007.
    • Received May 31, 2006.
    • Revision received December 13, 2006.
« Previous | Next Article »Table of Contents